Medicare Drug Price Negotiation

The Inflation Reduction Act “provides Medicare the ability to directly negotiate the prices of certain high expenditure, single source drugs without generic or biosimilar competition” for the first time.

How it works

CMS “selected ten drugs covered under Medicare Part D for the first cycle of negotiations for initial price applicability year 2026 and engaged in voluntary negotiations with the drug companies for the selected drugs.” The resulting prices, which “the statute refers to as Maximum Fair Prices (MFPs),” took effect January 1, 2026.

The process CMS describes is a genuine exchange rather than a price set unilaterally: “CMS developed an initial offer for each drug, consistent with the process described in the statute and the agency’s guidance, and each manufacturer responded with a counteroffer. CMS held three meetings with each participating drug company to discuss the offers and counteroffers, discuss evidence, and attempt to arrive at a mutually acceptable price.” Notably, “during the course of the negotiation process, CMS revised its offers for each of the drugs upward in response to these discussions.”

A second cycle covering additional drugs follows for 2027.

The eligibility limits matter

The scope is deliberately narrow, and reading it carefully prevents overstating what the program does:

• High expenditure, so only drugs representing substantial Medicare spending qualify.
• Single source, meaning no generic or biosimilar competitor exists.
• Part D first, with Part B drugs entering in later cycles.
• Time on market thresholds apply before a drug becomes eligible.

A drug facing generic competition is excluded on the reasoning that competition should already discipline its price. Whether that reasoning holds is exactly what the FTC’s specialty generic findings in Module 1 call into question, since those were generics marked up by hundreds to thousands of percent.

What it means for risk-bearing organizations

Directly, not much in the short term. Negotiation lowers what Medicare and beneficiaries pay for a small number of drugs. An ACO does not carry Part D in its benchmark, and the drugs affected are a narrow slice.

Indirectly, it matters more. It establishes that federal price-setting for drugs is now an operating program rather than a proposal, and the mechanism can be extended in scope by subsequent legislation. Anyone building a long-horizon financial model for drug spend should treat the policy environment as genuinely uncertain rather than assuming current trend.

Worth remembering: this program is frequently described as Medicare finally negotiating like a normal purchaser, and that framing overstates it in one direction while the objection that it is government price-fixing overstates it in the other. What the statute created is a bounded process covering selected single-source drugs, with defined offer and counteroffer steps, in which CMS raised its own offers during discussion. The rulemaking course made the general point that the operative details of a program live in its statutory constraints rather than its name. This is a good instance to practice on, because both the enthusiasm and the alarm are easier to evaluate once you know the eligibility criteria.

Key takeaways

• Medicare can negotiate prices for certain high expenditure, single source drugs without generic or biosimilar competition.
• Ten Part D drugs had negotiated Maximum Fair Prices effective January 1, 2026, with a second cycle for 2027.
• The process involved offers, counteroffers, and three meetings per manufacturer, with CMS revising offers upward.
• Direct effect on provider risk arrangements is small; the precedent for federal drug pricing is the larger consequence.

Sources

• CMS, Medicare Drug Price Negotiation Program: Negotiated Prices for Initial Price Applicability Year 2026 (opens in a new tab)
• FTC, Second Interim Staff Report on Prescription Drug Middlemen (January 2025) (opens in a new tab)